Qinglei Zhang1, Chongli Hao2, Guangzhou Cheng3, Lei Wang3, Xiang Wang3, Chang Li4, Juhui Qiu5, Kejia Ding5. 1. Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University Jinan, Shandong, China ; Department of Urology, Tengzhou Central People's Hospital Zaozhuang, Shangdong, China. 2. Department of Oncology, Tengzhou Central People's Hospital Zaozhuang, Shangdong, China. 3. Department of Urology, Tengzhou Central People's Hospital Zaozhuang, Shangdong, China. 4. Department of Pathology, Tengzhou Central People's Hospital Zaozhuang, Shangdong, China. 5. Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University Jinan, Shandong, China.
Abstract
PURPOSE: The aim of this study was to investigate the clinical significance of CD4(+) T cells in non-muscle-invasive bladder cancer (NMIBC) tissues in situ. METHODS: Immunohistochemistry was used to examine the distribution of CD4(+) T cells in 131 NMIBC tissues. Kaplan-Meier analysis and Cox proportional hazards regression models were applied to estimate overall survival (OS) and recurrence-free survival (RFS). RESULTS: NMIBC patients were divided into two groups based on the median frequency of CD4(+) T cells (median, 1/×400 high resolution). On univariate analysis, CD4(+) T cell density was inversely associated with overall survival (P = 0.01). In those patients with high CD4(+) T density, 5-year OS rates was only 77%, compared with 86% in those with low density, respectively. Although CD4(+) T cell density showed no prognostic significance for RFS (P = 0.36), 5-year RFS rates of patients with high CD4(+) T density (58%) was lower than those of patients with low CD4(+) T density (65%, respectively). By multivariate analysis, tumor infiltrating CD4(+) T cell density emerged as an independent prognostic factor for OS (HR, 2.75; P = 0.004). In addition, no association was found between CD4(+) T cell density and any clinicopathological variables (P > 0.05). CONCLUSION: Our findings suggest that CD4(+) T cells could potentially serve as a poor prognostic marker for patients with NMIBC.
PURPOSE: The aim of this study was to investigate the clinical significance of CD4(+) T cells in non-muscle-invasive bladder cancer (NMIBC) tissues in situ. METHODS: Immunohistochemistry was used to examine the distribution of CD4(+) T cells in 131 NMIBC tissues. Kaplan-Meier analysis and Cox proportional hazards regression models were applied to estimate overall survival (OS) and recurrence-free survival (RFS). RESULTS: NMIBC patients were divided into two groups based on the median frequency of CD4(+) T cells (median, 1/×400 high resolution). On univariate analysis, CD4(+) T cell density was inversely associated with overall survival (P = 0.01). In those patients with high CD4(+) T density, 5-year OS rates was only 77%, compared with 86% in those with low density, respectively. Although CD4(+) T cell density showed no prognostic significance for RFS (P = 0.36), 5-year RFS rates of patients with high CD4(+) T density (58%) was lower than those of patients with low CD4(+) T density (65%, respectively). By multivariate analysis, tumor infiltrating CD4(+) T cell density emerged as an independent prognostic factor for OS (HR, 2.75; P = 0.004). In addition, no association was found between CD4(+) T cell density and any clinicopathological variables (P > 0.05). CONCLUSION: Our findings suggest that CD4(+) T cells could potentially serve as a poor prognostic marker for patients with NMIBC.
Entities:
Keywords:
CD4; T cells; non-muscle-invasive bladder cancers (NMIBC); prognosis
Authors: O Nakano; M Sato; Y Naito; K Suzuki; S Orikasa; M Aizawa; Y Suzuki; I Shintaku; H Nagura; H Ohtani Journal: Cancer Res Date: 2001-07-01 Impact factor: 12.701
Authors: D L Lamm; B A Blumenstein; J D Crissman; J E Montie; J E Gottesman; B A Lowe; M F Sarosdy; R D Bohl; H B Grossman; T M Beck; J T Leimert; E D Crawford Journal: J Urol Date: 2000-04 Impact factor: 7.450
Authors: Alexandre Corthay; Dag K Skovseth; Katrin U Lundin; Egil Røsjø; Hilde Omholt; Peter O Hofgaard; Guttorm Haraldsen; Bjarne Bogen Journal: Immunity Date: 2005-03 Impact factor: 31.745
Authors: Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou Journal: Nat Med Date: 2004-08-22 Impact factor: 53.440
Authors: Gaynor J Bates; Stephen B Fox; Cheng Han; Russell D Leek; José F Garcia; Adrian L Harris; Alison H Banham Journal: J Clin Oncol Date: 2006-12-01 Impact factor: 44.544
Authors: E J Bromwich; P A McArdle; K Canna; D C McMillan; A-M McNicol; M Brown; M Aitchison Journal: Br J Cancer Date: 2003-11-17 Impact factor: 7.640
Authors: Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox Journal: Adv Anat Pathol Date: 2017-11 Impact factor: 3.875
Authors: Susanne Deininger; Peter Törzsök; Michael Mitterberger; Maximilian Pallauf; David Oswald; Christian Deininger; Lukas Lusuardi Journal: Cancers (Basel) Date: 2022-01-29 Impact factor: 6.639